| 1 | Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria | 2.3 | 12 | Citations (PDF) |
| 2 | A case of opsoclonus-myoclonus syndrome associated with breast cancer | 0.1 | 0 | Citations (PDF) |
| 3 | Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets | 8.2 | 38 | Citations (PDF) |
| 4 | Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae | 4.2 | 14 | Citations (PDF) |
| 5 | Real‐world clinical experience with serum
MOG
and
AQP4
antibody testing by live versus fixed cell‐based assay | 2.3 | 38 | Citations (PDF) |
| 6 | CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity | 2.3 | 8 | Citations (PDF) |
| 7 | Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD | 2.3 | 3 | Citations (PDF) |
| 8 | High‐Throughput Immunoassays for Cavin‐4 IgG: A Diagnostic Tool for Immune‐Mediated Rippling Muscle Disease | 2.3 | 2 | Citations (PDF) |
| 9 | Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity | 2.7 | 0 | Citations (PDF) |
| 10 | Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG–Positive NMOSD | 5.2 | 4 | Citations (PDF) |
| 11 | Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease | 0.7 | 15 | Citations (PDF) |
| 12 | Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease | 0.7 | 18 | Citations (PDF) |
| 13 | Peripheral nervous system manifestations of MOG antibody associated disease | 2.3 | 19 | Citations (PDF) |
| 14 | Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome | 1.7 | 1 | Citations (PDF) |
| 15 | Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder | 1.6 | 10 | Citations (PDF) |
| 16 | Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles | 2.4 | 2 | Citations (PDF) |
| 17 | Acute Optic Neuropathy in Older Adults | 3.7 | 10 | Citations (PDF) |
| 18 | Etiologies of Myelopathy in Uganda Based on Neuroimaging, Autoantibodies, and Next Generation Sequencing (S4.008) | 0.7 | 0 | Citations (PDF) |
| 19 | Paraneoplastic Neurologic Syndromes Associated with Testicular Germ Cell Tumors: Clinical and Serological Characteristics (S38.005) | 0.7 | 0 | Citations (PDF) |
| 20 | Identification of SKOR2 IgG as a Novel Biomarker of Paraneoplastic Neurologic Syndrome (N1.001) | 0.7 | 0 | Citations (PDF) |
| 21 | Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid | 4.6 | 48 | Citations (PDF) |
| 22 | Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005) | 0.7 | 0 | Citations (PDF) |
| 23 | Peripheral Nervous System Manifestations of MOG Antibody Associated Disease (P9-14.015) | 0.7 | 0 | Citations (PDF) |
| 24 | Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein (CAMKV) Autoimmune Encephalitis | 4.6 | 11 | Citations (PDF) |
| 25 | Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody–Associated Disease | 0.7 | 47 | Citations (PDF) |
| 26 | Seizure-Related Falls and Near Falls in LGI1-IgG Autoimmune Encephalitis | 1.6 | 2 | Citations (PDF) |
| 27 | Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder | 2.5 | 20 | Citations (PDF) |
| 28 | Frequency of Asymptomatic Optic Nerve Enhancement in 203 Patients With MOG Antibody-Associated Disease | 3.7 | 10 | Citations (PDF) |
| 29 | Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights | 4.6 | 14 | Citations (PDF) |
| 30 | Overview and Diagnostic Approach in Autoimmune Neurology | 0.6 | 9 | Citations (PDF) |
| 31 | B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity | 2.3 | 16 | Citations (PDF) |
| 32 | Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study | 2.7 | 14 | Citations (PDF) |
| 33 | Intracranial Pressure Elevation and MOGAD | 12.1 | 14 | Citations (PDF) |
| 34 | Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice | 3.7 | 12 | Citations (PDF) |
| 35 | Cerebellar Involvement During Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder | 0.7 | 0 | Citations (PDF) |
| 36 | Paraneoplastic Neurologic Syndromes Associated with Lymphomas | 0.7 | 0 | Citations (PDF) |
| 37 | ANNA1 Neurological Autoimmunity: A Comparative Analysis of Cancers, Neurological Phenotype and Coexisting Antibodies Across Age Demographics | 0.7 | 0 | Citations (PDF) |
| 38 | Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study | 0.7 | 5 | Citations (PDF) |
| 39 | Characterize GAD65-specific T cell Responses in Patients with Stiff-Person Syndrome and Type-I Diabetes. | 0.7 | 1 | Citations (PDF) |
| 40 | CDR2 and CDR2L Line Blot Performance in PCA-1/Anti-Yo Paraneoplastic Autoimmunity | 0.7 | 0 | Citations (PDF) |
| 41 | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica | 2.3 | 8 | Citations (PDF) |
| 42 | MOGandAQP4Antibodies among Children with Multiple Sclerosis and Controls | 4.6 | 33 | Citations (PDF) |
| 43 | Psychological and Financial Problems Among Female Staff Nurses: A Descriptive Study 2023, CIX, 274-278 | | 0 | Citations (PDF) |
| 44 | Cerebral Cortical Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease | 4.6 | 78 | Citations (PDF) |
| 45 | AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies | 1.7 | 12 | Citations (PDF) |
| 46 | Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis | 2.3 | 16 | Citations (PDF) |
| 47 | Sleep disturbances associated with DPPX autoantibodies: a case series | 2.7 | 12 | Citations (PDF) |
| 48 | A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder | 1.6 | 29 | Citations (PDF) |
| 49 | Autoimmune Encephalitis Criteria in Clinical Practice | 1.6 | 63 | Citations (PDF) |
| 50 | Immune checkpoint inhibitor‐associated central nervous system autoimmunity | 2.4 | 29 | Citations (PDF) |
| 51 | Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder | 4.2 | 47 | Citations (PDF) |
| 52 | Subacute Horizontal Diplopia, Jaw Dystonia, and Laryngospasm | 3.7 | 8 | Citations (PDF) |
| 53 | Alterations in Aquaporin‐4‐IgG Serostatus in 986 Patients: A Laboratory‐Based Longitudinal Analysis | 4.6 | 35 | Citations (PDF) |
| 54 | Tenascin‐R Autoimmunity: Isolated Tremor Reversed with Immunotherapy | 4.6 | 4 | Citations (PDF) |
| 55 | Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment (S5.005) | 0.7 | 1 | Citations (PDF) |
| 56 | Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial (S5.004) | 0.7 | 2 | Citations (PDF) |
| 57 | Paraneoplastic Neurologic Syndromes with ANNA-2/anti-Ri: a Contrasting Story of Two Cases (P5-5.026) | 0.7 | 1 | Citations (PDF) |
| 58 | Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS | 1.2 | 9 | Citations (PDF) |
| 59 | Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome | 2.7 | 3 | Citations (PDF) |
| 60 | Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria | 2.3 | 53 | Citations (PDF) |
| 61 | Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD? | 4.6 | 35 | Citations (PDF) |
| 62 | Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins | 4.6 | 17 | Citations (PDF) |
| 63 | Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome | 3.3 | 16 | Citations (PDF) |
| 64 | CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity | 3.3 | 9 | Citations (PDF) |
| 65 | Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder | 2.3 | 40 | Citations (PDF) |
| 66 | Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours | 4.2 | 25 | Citations (PDF) |
| 67 | Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension | 2.3 | 76 | Citations (PDF) |
| 68 | Exposure to TNF inhibitors is rare at MOGAD presentation | 1.2 | 11 | Citations (PDF) |
| 69 | Spectrum of sublytic astrocytopathy in neuromyelitis opticaBrain, 2022, 145, 1379-1390 | 5.9 | 48 | Citations (PDF) |
| 70 | AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder | 1.4 | 38 | Citations (PDF) |
| 71 | LGI1 antibody encephalitis: acute treatment comparisons and outcome | 4.2 | 136 | Citations (PDF) |
| 72 | OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis | 1.4 | 93 | Citations (PDF) |
| 73 | CASPR2‐IgG‐associated autoimmune seizures | 3.0 | 32 | Citations (PDF) |
| 74 | Autoimmune gastrointestinal dysmotility following SARS‐CoV‐2 infection successfully treated with intravenous immunoglobulin | 1.6 | 13 | Citations (PDF) |
| 75 | Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis | 3.7 | 45 | Citations (PDF) |
| 76 | Anti‐Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1 | 4.6 | 37 | Citations (PDF) |
| 77 | Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations | 1.9 | 66 | Citations (PDF) |
| 78 | An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond | 0.6 | 20 | Citations (PDF) |
| 79 | Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation | 1.4 | 18 | Citations (PDF) |
| 80 | Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease | 12.1 | 114 | Citations (PDF) |
| 81 | CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis | 1.9 | 36 | Citations (PDF) |
| 82 | Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients | 1.7 | 16 | Citations (PDF) |
| 83 | Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes | 3.7 | 65 | Citations (PDF) |
| 84 | Investigating the Immunopathogenic Mechanisms Underlying MOGAD | 4.6 | 11 | Citations (PDF) |
| 85 | Comparison of 1.5 Tesla and 3.0 Tesla Magnetic Resonance Imaging in the Evaluation of Acute Demyelinating Optic Neuritis | 0.8 | 11 | Citations (PDF) |
| 86 | Anti-complement Agents for Autoimmune Neurological Disease | 3.9 | 9 | Citations (PDF) |
| 87 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management | 1.6 | 300 | Citations (PDF) |
| 88 | Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults | 12.1 | 38 | Citations (PDF) |
| 89 | Longitudinal Retinal Changes in MOGAD | 4.6 | 58 | Citations (PDF) |
| 90 | A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder” | 2.5 | 2 | Citations (PDF) |
| 91 | Comprehensive Diabetes Autoantibody Laboratory-Based Clinical Service Testing in 6044 Consecutive Patients: Analysis of Age and Sex Effects | 1.0 | 2 | Citations (PDF) |
| 92 | Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics | 4.6 | 31 | Citations (PDF) |
| 93 | Neuroimaging features in inflammatory myelopathies: A review | 1.6 | 51 | Citations (PDF) |
| 94 | Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis | 3.3 | 6 | Citations (PDF) |
| 95 | SAkuraBONSAI: A Prospective, Open-label Study of Satralizumab Investigating Novel Imaging, Biomarker, and Clinical Outcomes in Patients with Aquaporin-4-IgG-seropositive (P15.AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P15-1.002) | 0.7 | 0 | Citations (PDF) |
| 96 | Paraneoplastic Cochleovestibulopathy: Clinical Presentations, Oncological and Serological Associations (S41.007) | 0.7 | 0 | Citations (PDF) |
| 97 | Neurofilament light chain levels differentiate between ischemic and inflammatory optic neuropathies (P17-12.003) | 0.7 | 0 | Citations (PDF) |
| 98 | Applicability of Autoimmune Encephalitis Criteria in Clinical Practice (S41.001) | 0.7 | 0 | Citations (PDF) |
| 99 | MOG-IgG1 and co-existence of neuronal autoantibodies | 2.3 | 51 | Citations (PDF) |
| 100 | Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies | 2.3 | 111 | Citations (PDF) |
| 101 | Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study | 2.3 | 19 | Citations (PDF) |
| 102 | Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD | 2.3 | 44 | Citations (PDF) |
| 103 | SMART syndrome: retrospective review of a rare delayed complication of radiation | 2.4 | 33 | Citations (PDF) |
| 104 | Paraneoplastic Myeloneuropathies | 0.7 | 41 | Citations (PDF) |
| 105 | Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis | 2.0 | 54 | Citations (PDF) |
| 106 | Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial | 1.4 | 40 | Citations (PDF) |
| 107 | Evaluation of cell-based and tissue-based immunofluorescent assays for detection of glial fibrillary acidic protein autoantibodies in the cerebrospinal fluid of dogs with meningoencephalitis of unknown origin and other central nervous system disorders | 0.3 | 5 | Citations (PDF) |
| 108 | Clinical spectrum of high-titre GAD65 antibodies | 4.2 | 177 | Citations (PDF) |
| 109 | Seizures and memory impairment induced by patient‐derived anti‐N‐methyl‐D‐aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin‐1 receptor antagonist | 3.0 | 42 | Citations (PDF) |
| 110 | Paraneoplastic neurological syndrome: an evolving story | 0.7 | 12 | Citations (PDF) |
| 111 | Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis | 4.4 | 16 | Citations (PDF) |
| 112 | Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker | 4.6 | 60 | Citations (PDF) |
| 113 | Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD | 4.6 | 100 | Citations (PDF) |
| 114 | Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity | 3.0 | 30 | Citations (PDF) |
| 115 | Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder | 3.7 | 41 | Citations (PDF) |
| 116 | Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker | 4.6 | 139 | Citations (PDF) |
| 117 | Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management | 4.2 | 143 | Citations (PDF) |
| 118 | Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management | 4.2 | 506 | Citations (PDF) |
| 119 | Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels | 0.7 | 20 | Citations (PDF) |
| 120 | MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study | 4.5 | 16 | Citations (PDF) |
| 121 | Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension | 1.4 | 11 | Citations (PDF) |
| 122 | Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders | 0.7 | 155 | Citations (PDF) |
| 123 | Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence | 1.4 | 11 | Citations (PDF) |
| 124 | CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies | 0.7 | 45 | Citations (PDF) |
| 125 | Myelin-oligodendrocyte glycoprotein antibody-associated disease | 13.7 | 509 | Citations (PDF) |
| 126 | Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS | 4.2 | 113 | Citations (PDF) |
| 127 | Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials | 18.3 | 134 | Citations (PDF) |
| 128 | Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers | 2.3 | 33 | Citations (PDF) |
| 129 | Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder | 2.5 | 34 | Citations (PDF) |
| 130 | Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders | 0.4 | 30 | Citations (PDF) |
| 131 | Autoimmune encephalitis antibody biomarkers: Frequency, age and sex associations (1579) | 0.7 | 0 | Citations (PDF) |
| 132 | Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578) | 0.7 | 1 | Citations (PDF) |
| 133 | Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies | 4.2 | 56 | Citations (PDF) |
| 134 | Collapsin Response-Mediator Protein 5–Associated Retinitis, Vitritis, and Optic Disc Edema | 5.8 | 48 | Citations (PDF) |
| 135 | Optic neuritis in the era of biomarkers | 4.1 | 72 | Citations (PDF) |
| 136 | Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis | 0.6 | 30 | Citations (PDF) |
| 137 | The frequency of longitudinally extensive transverse myelitis in MS: A population-based study | 1.4 | 47 | Citations (PDF) |
| 138 | Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients | 12.1 | 85 | Citations (PDF) |
| 139 | Randomized Placebo‐Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy | 4.6 | 158 | Citations (PDF) |
| 140 | IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS | 4.2 | 9 | Citations (PDF) |
| 141 | Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG | 4.2 | 38 | Citations (PDF) |
| 142 | Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies | 3.0 | 94 | Citations (PDF) |
| 143 | Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis | 0.6 | 77 | Citations (PDF) |
| 144 | Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis | 12.1 | 180 | Citations (PDF) |
| 145 | Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG–Associated Disorders | 12.1 | 21 | Citations (PDF) |
| 146 | Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm | 0.7 | 30 | Citations (PDF) |
| 147 | GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin‐Associated Ataxia and Neuropathy | 1.3 | 16 | Citations (PDF) |
| 148 | Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder | 12.1 | 94 | Citations (PDF) |
| 149 | Neurologic autoimmunity and immune checkpoint inhibitors | 0.7 | 149 | Citations (PDF) |
| 150 | Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events | 12.1 | 146 | Citations (PDF) |
| 151 | Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients | 1.4 | 174 | Citations (PDF) |
| 152 | Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD | 3.7 | 62 | Citations (PDF) |
| 153 | Contactin-1 autoimmunity | 3.7 | 36 | Citations (PDF) |
| 154 | High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display | 2.0 | 69 | Citations (PDF) |
| 155 | Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunctionBrain, 2020, 143, 1622-1625 | 5.9 | 3 | Citations (PDF) |
| 156 | Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder | 0.7 | 219 | Citations (PDF) |
| 157 | Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide | 1.6 | 391 | Citations (PDF) |
| 158 | Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis | 2.7 | 21 | Citations (PDF) |
| 159 | International multicenter examination of MOG antibody assays | 3.7 | 284 | Citations (PDF) |
| 160 | GFAP IgG associated inflammatory polyneuropathy | 1.7 | 22 | Citations (PDF) |
| 161 | The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody | 5.8 | 358 | Citations (PDF) |
| 162 | Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR | 1.5 | 44 | Citations (PDF) |
| 163 | AMPAR Autoimmunity: Neurological, Oncological and Serological Accompaniments. (4689) | 0.7 | 0 | Citations (PDF) |
| 164 | Lesion Evolution on MRI in Myelitis Associated with MS, Aquaporin-4-IgG and Myelin Oligodendrocyte Glycoprotein-IgG (4913) | 0.7 | 0 | Citations (PDF) |
| 165 | Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelitis (2620) | 0.7 | 0 | Citations (PDF) |
| 166 | LGI1 Antibody Encephalitis: Treatments and Long-term Outcome (3947) | 0.7 | 1 | Citations (PDF) |
| 167 | Improved Accuracy in Myasthenia Gravis Using Combinatorial Algorithmic Autoantibody Testing (2679) | 0.7 | 0 | Citations (PDF) |
| 168 | A Prospective Clinical Validation of Neuronal Intermediate Filament IgGs (2195) | 0.7 | 0 | Citations (PDF) |
| 169 | Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders (1906) | 0.7 | 0 | Citations (PDF) |
| 170 | Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis | 4.2 | 69 | Citations (PDF) |
| 171 | Phosphodiesterase 10A IgG | 0.7 | 79 | Citations (PDF) |
| 172 | Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis | 26.4 | 271 | Citations (PDF) |
| 173 | Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology | 0.7 | 37 | Citations (PDF) |
| 174 | Amphiphysin-IgG autoimmune neuropathy | 0.7 | 70 | Citations (PDF) |
| 175 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial | 46.9 | 713 | Citations (PDF) |
| 176 | Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG | 0.7 | 58 | Citations (PDF) |
| 177 | Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica | 0.7 | 100 | Citations (PDF) |
| 178 | Optical coherence tomography is highly sensitive in detecting prior optic neuritis | 0.7 | 77 | Citations (PDF) |
| 179 | Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up | 4.2 | 54 | Citations (PDF) |
| 180 | Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder | 26.4 | 839 | Citations (PDF) |
| 181 | GABA
A
receptor autoimmunity | 3.7 | 62 | Citations (PDF) |
| 182 | Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disordersBrain, 2019, 142, 1310-1323 | 5.9 | 201 | Citations (PDF) |
| 183 | Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability | 3.0 | 68 | Citations (PDF) |
| 184 | A multicenter comparison of MOG-IgG cell-based assays | 0.7 | 233 | Citations (PDF) |
| 185 | A mouse model of seizures in anti–N‐methyl‐d‐aspartate receptor encephalitis | 3.0 | 69 | Citations (PDF) |
| 186 | Neurochondrin neurological autoimmunity | 3.7 | 41 | Citations (PDF) |
| 187 | Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 | 6.5 | 132 | Citations (PDF) |
| 188 | Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody | 12.1 | 364 | Citations (PDF) |
| 189 | Age is a critical determinant in recovery from multiple sclerosis relapses | 2.3 | 66 | Citations (PDF) |
| 190 | The Mayo Clinic Center for MS and Autoimmune Neurology Biorepository (CMSAN): Infrastructure Development (P1.9-069) | 0.7 | 0 | Citations (PDF) |
| 191 | Paraneoplastic Phosphodiesterase 10A Neurological Autoimmunity Unmasked by Immune Checkpoint Inhibitor Therapy (S21.002) | 0.7 | 0 | Citations (PDF) |
| 192 | CSF kappa Free Light Chains as a Potential Quantitative Alternative to Oligoclonal Bands in Multiple Sclerosis (S37.001) | 0.7 | 2 | Citations (PDF) |
| 193 | Age and relapse location: Critical determinants in recovery from multiple sclerosis relapses (S6.009) | 0.7 | 0 | Citations (PDF) |
| 194 | The Frequency of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study (P4.2-055) | 0.7 | 0 | Citations (PDF) |
| 195 | CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes | 2.0 | 65 | Citations (PDF) |
| 196 | MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy | 1.4 | 34 | Citations (PDF) |
| 197 | Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders | 3.7 | 86 | Citations (PDF) |
| 198 | Calcium channel autoimmunity: Cerebellar ataxia and lambert‐eaton syndrome coexisting | 1.6 | 10 | Citations (PDF) |
| 199 | Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM | 1.6 | 22 | Citations (PDF) |
| 200 | Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis | 4.6 | 729 | Citations (PDF) |
| 201 | GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies | 1.8 | 30 | Citations (PDF) |
| 202 | Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis | 12.1 | 23 | Citations (PDF) |
| 203 | Elevated LGI1‐IgG CSF index predicts worse neurological outcome | 2.3 | 48 | Citations (PDF) |
| 204 | Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis | 5.8 | 133 | Citations (PDF) |
| 205 | LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes | 4.2 | 224 | Citations (PDF) |
| 206 | Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody–Positive Meningoencephalitis | 0.8 | 52 | Citations (PDF) |
| 207 | Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases | 0.7 | 125 | Citations (PDF) |
| 208 | Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men | 4.2 | 18 | Citations (PDF) |
| 209 | Paraneoplastic neuronal intermediate filament autoimmunity | 0.7 | 75 | Citations (PDF) |
| 210 | Area postrema syndrome | 0.7 | 182 | Citations (PDF) |
| 211 | Population-based study of “no evident disease activity” in MS | 3.7 | 6 | Citations (PDF) |
| 212 | Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine‐rich glioma‐inactivated protein 1 | 2.0 | 35 | Citations (PDF) |
| 213 | Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year | 1.7 | 201 | Citations (PDF) |
| 214 | LGI1 and CASPR2 neurological autoimmunity in children | 4.6 | 67 | Citations (PDF) |
| 215 | Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome | 3.0 | 408 | Citations (PDF) |
| 216 | Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction | 1.7 | 113 | Citations (PDF) |
| 217 | Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders | 12.1 | 394 | Citations (PDF) |
| 218 | Autoimmune septin-5 cerebellar ataxia | 3.7 | 63 | Citations (PDF) |
| 219 | Neuroimmune disorders of the central nervous system in children in the molecular era | 18.3 | 59 | Citations (PDF) |
| 220 | Seizure Semiologies and Effects of Anti-epileptic Drugs in Patients with Leucine-rich glioma-inactivated-1 ligand antibody (LGI1-Ab) Autoimmune Epilepsy (S11.003) | 0.7 | 1 | Citations (PDF) |
| 221 | Post-Transplant Autoimmune Encephalitis (P5.382) | 0.7 | 0 | Citations (PDF) |
| 222 | Elevated LGI1-IgG CSF index predicts worse neurological outcome (P1.397) | 0.7 | 0 | Citations (PDF) |
| 223 | Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder | 12.1 | 49 | Citations (PDF) |
| 224 | Microtubule‐associated protein 1B: Novel paraneoplastic biomarker | 4.6 | 96 | Citations (PDF) |
| 225 | Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients | 4.6 | 547 | Citations (PDF) |
| 226 | Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica | 5.8 | 77 | Citations (PDF) |
| 227 | Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders | 4.2 | 71 | Citations (PDF) |
| 228 | Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder | 3.7 | 65 | Citations (PDF) |
| 229 | Expanded phenotypes and outcomes among 256
LGI
1/
CASPR
2‐
I
g
G
–positive patients | 4.6 | 340 | Citations (PDF) |
| 230 | Predictive models in the diagnosis and treatment of autoimmune epilepsy | 3.0 | 158 | Citations (PDF) |
| 231 | Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)Brain, 2017, 140, 2415-2425 | 5.9 | 204 | Citations (PDF) |
| 232 | PRES leading to the diagnosis of McArdle disease | 1.0 | 1 | Citations (PDF) |
| 233 | IgLON5 antibody | 3.7 | 242 | Citations (PDF) |
| 234 | Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management | 2.3 | 48 | Citations (PDF) |
| 235 | B-cell–targeted therapies in relapsing forms of MS | 3.7 | 15 | Citations (PDF) |
| 236 | Clinical‐pathologic correlations in voltage‐gated Kv1 potassium channel complex‐subtyped autoimmune painful polyneuropathy | 1.6 | 22 | Citations (PDF) |
| 237 | Breast cancer-related paraneoplastic neurologic disease | 1.8 | 29 | Citations (PDF) |
| 238 | Autoimmune Neurology of the Central Nervous System | 0.6 | 22 | Citations (PDF) |
| 239 | Ganglioside composite testing identifies immune responsive motor-onset MADSAM and MMN (P5.111) | 0.7 | 0 | Citations (PDF) |
| 240 | Microtubule Associated Protein (MAP) 1B: Antigen of PCA-2 IgG, Biomarker of Small-Cell Lung Carcinoma-related Paraneoplastic Neurological Autoimmunity (S41.007) | 0.7 | 0 | Citations (PDF) |
| 241 | Area postrema syndrome more specific than extension of lesion on MRI for Neuromyelitis Optica Spectrum Disorder (P6.387) | 0.7 | 0 | Citations (PDF) |
| 242 | Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) (P6.386) | 0.7 | 1 | Citations (PDF) |
| 243 | Specificity of glial fibrillary acidic protein IgG autoantibody (GFAP-IgG) for Autoimmune Meningoencephalomyelitis Diagnosis (S20.002) | 0.7 | 3 | Citations (PDF) |
| 244 | Case Control Analysis of Glycine Receptor Autoimmunity (P5.125) | 0.7 | 0 | Citations (PDF) |
| 245 | Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin‐4 channelopathies: a decade later | 2.6 | 222 | Citations (PDF) |
| 246 | Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum | 4.6 | 338 | Citations (PDF) |
| 247 | Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy | 12.1 | 568 | Citations (PDF) |
| 248 | Autoantibody-Associated Central Nervous System Neurologic Disorders | 1.2 | 33 | Citations (PDF) |
| 249 | P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments | 1.6 | 104 | Citations (PDF) |
| 250 | Discriminating long myelitis of neuromyelitis optica from sarcoidosis | 4.6 | 181 | Citations (PDF) |
| 251 | Clinical utility of testing AQP4-IgG in CSF | 3.7 | 142 | Citations (PDF) |
| 252 | Placebo-controlled study in neuromyelitis optica—Ethical and design considerations | 2.3 | 72 | Citations (PDF) |
| 253 | Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy | 1.6 | 11 | Citations (PDF) |
| 254 | Metabotropic glutamate receptor type 1 autoimmunity | 0.7 | 98 | Citations (PDF) |
| 255 | Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis | 1.2 | 7 | Citations (PDF) |
| 256 | Clinical, Radiographic and Pathological Features of CLIPPERS (Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids) (P6.109) | 0.7 | 0 | Citations (PDF) |
| 257 | Rho GTPase Activating Protein 26 (ARHGAP26)-Igg Autoimmunity: Frequency and Clinical Associations (P3.346) | 0.7 | 0 | Citations (PDF) |
| 258 | Recoverin Antibody: Ophthalmologic & Oncologic Significance (P6.131) | 0.7 | 1 | Citations (PDF) |
| 259 | Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum: A Comparison of Two Ethnically Divergent Populations (P3.003) | 0.7 | 0 | Citations (PDF) |
| 260 | Medusa Head-Type Neuronal Autoantibody Inositol Triphosphate Receptor-1 (ITPR1)-IgG: Frequency, Clinical Phenotype and Cancer Associations (P5.300) | 0.7 | 0 | Citations (PDF) |
| 261 | Ring-Enhancing Spinal Cord Lesions in Neuromyelitis Optica Spectrum Disorder (P4.145) | 0.7 | 0 | Citations (PDF) |
| 262 | Discriminating Long Myelitis of Neuromyelitis Optica Spectrum Disorders from Sarcoidosis (P4.152) | 0.7 | 0 | Citations (PDF) |
| 263 | Short Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum Disorders | 12.1 | 239 | Citations (PDF) |
| 264 | Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry | 1.7 | 7 | Citations (PDF) |
| 265 | Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures | 3.7 | 205 | Citations (PDF) |
| 266 | Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis | 0.7 | 104 | Citations (PDF) |
| 267 | Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond | 2.7 | 49 | Citations (PDF) |
| 268 | Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy | 1.6 | 28 | Citations (PDF) |
| 269 | Autoimmune Epilepsy | 1.2 | 64 | Citations (PDF) |
| 270 | Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults | 12.1 | 108 | Citations (PDF) |
| 271 | Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions | 0.7 | 54 | Citations (PDF) |
| 272 | Relapses and disability accumulation in progressive multiple sclerosis | 0.7 | 108 | Citations (PDF) |
| 273 | Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes | 2.7 | 67 | Citations (PDF) |
| 274 | Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes | 1.8 | 72 | Citations (PDF) |
| 275 | Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients (I4-4B) | 0.7 | 0 | Citations (PDF) |
| 276 | Autoimmune Encephalitis in the ICU: Serological Spectrum, Clinical Courses, Complications and Outcomes (P4.046) | 0.7 | 0 | Citations (PDF) |
| 277 | Ma2 Autoantibody-Negative Multifocal Paraneoplastic Neurological Disorder Associated with Metastatic Testicular Cancer. (P4.049) | 0.7 | 2 | Citations (PDF) |
| 278 | Autoimmune Encephalitis in the ICU: Serological Spectrum, Clinical Courses, Complications and Outcomes (I4-5A) | 0.7 | 0 | Citations (PDF) |
| 279 | Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients (P2.111) | 0.7 | 1 | Citations (PDF) |
| 280 | Prospective Evaluation of Maintenance Plasma Exchange (mPLEX) for Attack Prevention in Neuromyelitis Optica Spectrum Disorder: Preliminary Feasibility, Safety, and Efficacy Data (P5.265) | 0.7 | 0 | Citations (PDF) |
| 281 | Short Myelitis Lesions in Aquaporin-4-IgG-positive Neuromyelitis Optica Spectrum Disorders (S46.005) | 0.7 | 0 | Citations (PDF) |
| 282 | Neural Autoantibody Clusters Aid Diagnosis of Cancer | 4.5 | 70 | Citations (PDF) |
| 283 | Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis | 12.1 | 55 | Citations (PDF) |
| 284 | Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop | 0.7 | 3 | Citations (PDF) |
| 285 | The neurologic significance of celiac disease biomarkers | 0.7 | 59 | Citations (PDF) |
| 286 | Evaluation of aquaporin‐4 antibody assays | 0.8 | 135 | Citations (PDF) |
| 287 | Teaching Neuro
Images
: MRI in advanced neuromyelitis optica | 0.7 | 6 | Citations (PDF) |
| 288 | NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging | 1.6 | 13 | Citations (PDF) |
| 289 | MRI Findings in Autoimmune Voltage-Gated Potassium Channel Complex Encephalitis with Seizures: One Potential Etiology for Mesial Temporal Sclerosis | 1.7 | 111 | Citations (PDF) |
| 290 | DPPX potassium channel antibody | 0.7 | 303 | Citations (PDF) |
| 291 | Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study | 13.7 | 80 | Citations (PDF) |
| 292 | Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin‐4 channelopathies | 0.8 | 19 | Citations (PDF) |
| 293 | Hydrocephalus in Neuromyelitis Optica (P2.270) | 0.7 | 0 | Citations (PDF) |
| 294 | AQP4-IgG Assays Comparison in Laboratory Clinical Serivce (S63.004) | 0.7 | 1 | Citations (PDF) |
| 295 | DPPX Autoantibody: Frequency, Clinical Accompaniments and Outcomes (S40.001) | 0.7 | 1 | Citations (PDF) |
| 296 | Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study | 13.7 | 387 | Citations (PDF) |
| 297 | Teaching Neuro
Images
: Diagnostic utility of FDG-PET in neurolymphomatosis | 0.7 | 7 | Citations (PDF) |
| 298 | [18F]-Fluorodeoxyglucose–Positron Emission Tomography in Patients With Active Myelopathy | 1.9 | 43 | Citations (PDF) |
| 299 | Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel | 5.0 | 53 | Citations (PDF) |
| 300 | Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays | 3.8 | 77 | Citations (PDF) |
| 301 | Autoimmune chorea in adults | 0.7 | 121 | Citations (PDF) |
| 302 | Insights From LGI1 and CASPR2 Potassium Channel Complex Autoantibody Subtyping | 12.1 | 177 | Citations (PDF) |
| 303 | Glycine Receptor Autoimmune Spectrum With Stiff-Man Syndrome Phenotype | 12.1 | 204 | Citations (PDF) |
| 304 | GABA
B
receptor autoantibody frequency in service serologic evaluation | 0.7 | 124 | Citations (PDF) |
| 305 | Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica | 0.7 | 241 | Citations (PDF) |
| 306 | Childhood Onset of Stiff-Man Syndrome | 12.1 | 84 | Citations (PDF) |
| 307 | A Mathematical Analysis of Neural Autoantibody Clusters Encountered in Sera of 78,889 Patients Undergoing Comprehensive Paraneoplastic Autoantibody Evaluation (S29.006) | 0.7 | 0 | Citations (PDF) |
| 308 | Autoimmune Epilepsy | 6.8 | 356 | Citations (PDF) |
| 309 | Statin therapy and multiple sclerosis disability in a population-based cohort | 2.3 | 12 | Citations (PDF) |
| 310 | Stiff-Man Syndrome and Variants | 6.8 | 300 | Citations (PDF) |
| 311 | Effects of Age and Sex on Aquaporin-4 Autoimmunity | 6.8 | 107 | Citations (PDF) |
| 312 | Chronic pain as a manifestation of potassium channel-complex autoimmunity | 0.7 | 174 | Citations (PDF) |
| 313 | Adult-Onset Opsoclonus-Myoclonus Syndrome | 6.8 | 200 | Citations (PDF) |
| 314 | Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage | 1.2 | 33 | Citations (PDF) |
| 315 | Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients | 1.2 | 25 | Citations (PDF) |
| 316 | Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol | 4.6 | 28 | Citations (PDF) |
| 317 | Neuronal Voltage-Gated Potassium Channel Complex Autoimmunity in Children | 1.2 | 59 | Citations (PDF) |
| 318 | Pseudopseudoseizures: Conditions That May Mimic Psychogenic Non-Epileptic Seizures | 2.7 | 28 | Citations (PDF) |
| 319 | Psychiatric Manifestations of Voltage-Gated Potassium-Channel Complex Autoimmunity | 1.5 | 44 | Citations (PDF) |
| 320 | Purkinje Cell Cytoplasmic Autoantibody Type 1 Accompaniments | 6.8 | 111 | Citations (PDF) |
| 321 | Large Kindred Evaluation of Mitofusin 2 Novel Mutation, Extremes of Neurologic Presentations, and Preserved Nerve Mitochondria | 6.8 | 28 | Citations (PDF) |
| 322 | Autoimmune Myelopathies | 0.6 | 12 | Citations (PDF) |
| 323 | Serology of celiac disease in gluten-sensitive ataxia or neuropathy: Role of deamidated gliadin antibody | 1.7 | 26 | Citations (PDF) |
| 324 | Paraneoplastic encephalomyelopathies: pathology and mechanisms | 5.8 | 160 | Citations (PDF) |
| 325 | Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis | 1.3 | 37 | Citations (PDF) |
| 326 | Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination | 6.8 | 197 | Citations (PDF) |
| 327 | Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica | 6.8 | 36 | Citations (PDF) |
| 328 | Sleep Manifestations of Voltage-Gated Potassium Channel Complex Autoimmunity | 6.8 | 114 | Citations (PDF) |
| 329 | Reply to Duprez et al. and List et al. regarding chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroidsBrain, 2011, 134, e186-e186 | 5.9 | 2 | Citations (PDF) |
| 330 | IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES | 0.6 | 39 | Citations (PDF) |
| 331 | An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study | 13.7 | 53 | Citations (PDF) |
| 332 | Intractable vomiting as the initial presentation of neuromyelitis optica | 4.6 | 186 | Citations (PDF) |
| 333 | Positron Emission Tomography–Computed Tomography in Paraneoplastic Neurologic Disorders | 6.8 | 140 | Citations (PDF) |
| 334 | Absence of cortical demyelination in neuromyelitis optica | 0.7 | 109 | Citations (PDF) |
| 335 | Paraneoplastic Jaw Dystonia and Laryngospasm With Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri) | 6.8 | 97 | Citations (PDF) |
| 336 | Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response | 1.9 | 182 | Citations (PDF) |
| 337 | Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)Brain, 2010, 133, 2626-2634 | 5.9 | 357 | Citations (PDF) |
| 338 | Peripherin-IgG association with neurologic and endocrine autoimmunity | 3.8 | 35 | Citations (PDF) |
| 339 | Isolated Sympathetic Failure With Autoimmune Autonomic Ganglionopathy | 1.2 | 15 | Citations (PDF) |
| 340 | Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Case–Control Study | 1.5 | 13 | Citations (PDF) |
| 341 | Humoral Pattern II Multiple Sclerosis Pathology Not Associated With Neuromyelitis Optica IgG | 6.8 | 7 | Citations (PDF) |
| 342 | Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders | 0.7 | 207 | Citations (PDF) |
| 343 | Treatment of Neuromyelitis Optica With Mycophenolate Mofetil | 6.8 | 299 | Citations (PDF) |
| 344 | Diagnosis of Neuromyelitis Spectrum Disorders | 6.8 | 91 | Citations (PDF) |
| 345 | Reversible Extralimbic Paraneoplastic Encephalopathies With Large Abnormalities on Magnetic Resonance Images | 6.8 | 30 | Citations (PDF) |
| 346 | Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease | 6.8 | 33 | Citations (PDF) |
| 347 | Ganglionic Acetylcholine Receptor Autoantibody | 6.8 | 158 | Citations (PDF) |
| 348 | AQP4-IgG Immunoprecipitation Assay Optimization | 0.6 | 11 | Citations (PDF) |
| 349 | Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4–Expressing Cells | 6.8 | 114 | Citations (PDF) |
| 350 | Uncertain BENEFIT of early interferon beta-1b treatment | 13.7 | 6 | Citations (PDF) |
| 351 | 122. Voltage-gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease | 1.0 | 0 | Citations (PDF) |
| 352 | Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies | 6.8 | 3 | Citations (PDF) |
| 353 | Neural Autoantibody Profile of Primary Achalasia | 1.5 | 68 | Citations (PDF) |
| 354 | Autoimmune myelopathy associated with collapsin response‐mediator protein‐5 immunoglobulin G | 4.6 | 73 | Citations (PDF) |
| 355 | Neuromyelitis Optica and Non–Organ-Specific Autoimmunity | 6.8 | 551 | Citations (PDF) |
| 356 | Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal Dysmotility | 5.0 | 108 | Citations (PDF) |
| 357 | Clinical spectrum of voltage-gated potassium channel autoimmunity | 0.7 | 277 | Citations (PDF) |
| 358 | Aquaporin-4 Autoantibodies in a Paraneoplastic Context | 6.8 | 189 | Citations (PDF) |
| 359 | Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease | 6.8 | 178 | Citations (PDF) |
| 360 | NMO-IgG predicts the outcome of recurrent optic neuritis | 0.7 | 346 | Citations (PDF) |
| 361 | Neuromyelitis Optica: A New Perspective | 1.2 | 34 | Citations (PDF) |
| 362 | Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders | 0.7 | 256 | Citations (PDF) |
| 363 | CLARIFICATION On CNS FACTORS IN CHILDHOOD MS | 0.0 | 0 | Citations (PDF) |
| 364 | Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica | 0.7 | 486 | Citations (PDF) |
| 365 | Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosisBrain, 2007, 130, 1194-1205 | 5.9 | 696 | Citations (PDF) |
| 366 | Whole-Body Tremulousness | 6.8 | 43 | Citations (PDF) |
| 367 | The Pathology of MS | 0.8 | 99 | Citations (PDF) |
| 368 | A secondary progressive clinical course is uncommon in neuromyelitis optica | 0.7 | 326 | Citations (PDF) |
| 369 | Neuromyelitis optica: Changing concepts | 1.7 | 106 | Citations (PDF) |
| 370 | The spectrum of neuromyelitis optica | 13.7 | 2,091 | Citations (PDF) |
| 371 | Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyramidal, and Spinal Cord Dysfunction | 1.9 | 232 | Citations (PDF) |
| 372 | Revised diagnostic criteria for neuromyelitis optica | 0.7 | 2,564 | Citations (PDF) |
| 373 | Inflammatory transverse myelitis: evolving concepts | 2.4 | 63 | Citations (PDF) |
| 374 | Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis | 6.8 | 72 | Citations (PDF) |
| 375 | Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis | 4.6 | 576 | Citations (PDF) |
| 376 | Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression | 6.8 | 688 | Citations (PDF) |
| 377 | Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis | 6.8 | 55 | Citations (PDF) |
| 378 | Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis | 6.8 | 503 | Citations (PDF) |
| 379 | Brain Abnormalities in Neuromyelitis Optica | 6.8 | 658 | Citations (PDF) |
| 380 | MRI findings in benign multiple sclerosis are variable | 2.7 | 9 | Citations (PDF) |
| 381 | Amphiphysin autoimmunity: Paraneoplastic accompaniments | 4.6 | 343 | Citations (PDF) |
| 382 | Quality of Life Is Favorable for Most Patients With Multiple Sclerosis | 6.8 | 122 | Citations (PDF) |
| 383 | Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study | 4.6 | 202 | Citations (PDF) |
| 384 | Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome | 4.6 | 317 | Citations (PDF) |
| 385 | A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis | 46.9 | 3,172 | Citations (PDF) |
| 386 | Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments | 4.6 | 318 | Citations (PDF) |
| 387 | The Oxfordshire Community Stroke Project classification: Correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke | 1.0 | 86 | Citations (PDF) |
| 388 | The orpington prognostic scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke | 1.0 | 9 | Citations (PDF) |
| 389 | OKT3 neurotoxicity presenting as akinetic mutism | 1.4 | 31 | Citations (PDF) |
| 390 | Reversible Myelopathy in a 34-Year-Old Man With Vitamin B12 Deficiency | 1.9 | 40 | Citations (PDF) |
| 391 | Traumatic bilateral carotid dissection with concomitant cerebral infarction | 0.7 | 10 | Citations (PDF) |
| 392 | Rapid Weaning from Mechanical Ventilator in Acute Cervical Cord Multiple Sclerosis Lesion After Steroids | 1.5 | 6 | Citations (PDF) |
| 393 | Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka | 4.2 | 27 | Citations (PDF) |
| 394 | MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis | 4.2 | 3 | Citations (PDF) |
| 395 | Brain atrophy patterns in anti-IgLON5 disease | 5.9 | 6 | Citations (PDF) |
| 396 | Cytokine, Chemokine, and Neurofilament Light Chain Signatures in
LGI1
Autoimmune Encephalitis | 2.3 | 12 | Citations (PDF) |
| 397 | Unveiling Misdiagnosis: Rethinking Seronegative NMOSD | 2.3 | 1 | Citations (PDF) |
| 398 | Frequency of Seroconversion in Aquaporin‐4 Antibody Testing: Insights From Real‐World Data | 2.3 | 0 | Citations (PDF) |
| 399 | Amaurosis Fugax Dolorosa | 3.7 | 2 | Citations (PDF) |
| 400 | Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies | 1.4 | 2 | Citations (PDF) |
| 401 | Anti‐γ‐aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights | 3.0 | 3 | Citations (PDF) |
| 402 | Outcomes in Patients With Immune Checkpoint Inhibitor–Related Myopathy and Prolonged Follow-Up | 3.7 | 6 | Citations (PDF) |
| 403 | Testicular Cancer–Associated Paraneoplastic Neurologic Syndromes | 5.2 | 1 | Citations (PDF) |
| 404 | Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy | 0.7 | 0 | Citations (PDF) |
| 405 | Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies | 2.3 | 4 | Citations (PDF) |
| 406 | Multiple sclerosis research in 2025: earlier diagnosis and halting progression | 13.7 | 2 | Citations (PDF) |
| 407 | OCT-Based Differentiation of First Acute Optic Neuritis | 3.7 | 5 | Citations (PDF) |
| 408 | Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD | 0.7 | 4 | Citations (PDF) |
| 409 | Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive
NMOSD | 2.3 | 0 | Citations (PDF) |
| 410 | Reader Response: Eculizumab Use in Neuromyelitis Optica Spectrum Disorders | 0.7 | 0 | Citations (PDF) |
| 411 | The cascade to pathogenicity in autoantibody-mediated CNS diseases | 5.9 | 2 | Citations (PDF) |
| 412 | Long‐Term Outcomes in Stiff Person Spectrum Disorder | 2.4 | 0 | Citations (PDF) |
| 413 | PDE10A-IgG Neurological Autoimmunity: Expanded Clinical Phenotypes and Immunologic Observations. (S30.003) | 0.7 | 0 | Citations (PDF) |
| 414 | IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD | 12.1 | 0 | Citations (PDF) |
